BioCorRx (BICX) Total Non-Current Liabilities (2012 - 2024)

BioCorRx has disclosed Total Non-Current Liabilities across 10 years of filings, most recently posting $12.7 million for Q4 2024.

• Total Non-Current Liabilities for Q4 2024 came in at $12.7 million, up 23.85% year-over-year; the trailing twelve-month figure through Dec 2024 was $12.7 million (up 23.85% YoY), and the FY2024 annual result was $12.7 million, up 23.85% from the prior year.
• Total Non-Current Liabilities came in at $12.7 million for Q4 2024 at BioCorRx, up from $12.6 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $12.7 million in Q4 2024 to a low of $9.0 million in Q4 2022.
• The 3-year median for Total Non-Current Liabilities is $11.3 million (2024), against an average of $11.2 million.
• Across the five-year window, Total Non-Current Liabilities rose 14.71% in 2023 and climbed 23.85% in 2024, its largest moves.
• BioCorRx's Total Non-Current Liabilities stood at $9.0 million in 2022, then grew by 14.71% to $10.3 million in 2023, then grew by 23.85% to $12.7 million in 2024.
• The last three Total Non-Current Liabilities figures came in at $12.7 million (Q4 2024), $12.6 million (Q3 2024), and $11.5 million (Q2 2024), per Business Quant data.